Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers
A Single-center, Randomized, Controlled, Open-label Study to Investigate the Nicotine Pharmacokinetic Profiles and Subjective Effects of Four Variants of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Title:
Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers
Who carried out the research? This research was sponsored and funded by Philip Morris Products S.A.
What public involvement there was in the study? The study recruited 31 healthy adults who were currently smoking.
Where and when the study took place The study was conducted at a clinical trial facility managed by a contract research organization in Belfast, Northern Ireland, from March 15th to August 18th 2022.
Why was the research needed? The research was needed to understand the pharmacokinetic profiles of four variants of a nicotine pouch.
What were the main questions studied? The study measured the nicotine absorption of the four variants of nicotine pouch (NP-1; NP-2; NP-3; NP-4) together with two nicotine pouches marketed by other companies (Zyn-NP and Velo-NP). Participants were also asked to evaluate their experience of using the nicotine pouches.
Who participated in the study? The study recruited 31 healthy, male or female, adults aged between 21 and 65 years who were currently smoking. The subjects did not plan to quit using tobacco and/or nicotine products within the next 3 months and had smoked continuously for at least the last 3 years prior to joining the study..
Each subject was given full and adequate oral and written information about the nature, purpose, possible risks and benefits of the study. Once each subject had received all the necessary information, and if he/she agreed to participate, this was documented in an Informed Consent Form with the date, time and signature of both the subject and the Investigator.
Subjects were informed that they were free to withdraw from the study at any time.
What treatments or interventions did the participants take/receive? The participants were requested to use a tobacco-free nicotine pouch for a period of 30 minutes. Blood samples were taken before, during, and after the product use period.
Participants were also asked to evaluate their experience of using the nicotine pouches, using the Product Evaluation Scale (PES).
The PES is composed of seven items which address the degree to which subjects experience seven different effects (Product Satisfaction, Psychological Rewards, Aversion, Craving Relief, Easy to Use, Comfortable Using, Concerned about Dependence) as a result of using the investigational products, rated on a 7 point scale from 1 = "not at all" to 7 = "extremely."
What happened during the study? The study was conducted with six periods and six sequences in a cross-over design. On Day -1, subjects were randomized to one of the six study sequences.
After enrollment, subjects performed a product test with Nicotine Pouch 1.0 (NP-1) for 30 minutes (± 1 minute). One NP-1 nicotine pouch was placed between the upper lip and the gum for 30 minutes and subjects were instructed not to manipulate the pouch with the tongue or lips.
After the product test, subjects were required to abstain from any nicotine/tobacco-containing product use until the first product use on Day 1.
On Day 1 to Day 3, after at least 8 hours of abstinence from any nicotine/tobacco-containing products (nicotine wash-out), subjects used one variant of NP 1.0, Velo-NP, or Zyn-NP according to the randomized product use sequence for 30 minutes (± 1 minute). The used NP were collected for long-term storage to determine the residual nicotine after product use to estimate the amount of nicotine delivered during the 30-minute use period.
Subjects completed questionnaires about product evaluation, craving, and liking assessments.
In the morning on Day 1, 12 blood samples were collected for determination of nicotine concentration. Additional blood samples were taken for determination of the nicotine concentration on Day 2 and Day 3.
After Discharge at Day 3, the subjects entered a 3-day Safety Follow-Up period during which adverse reactions associated with product use reported by the subjects were collected and the follow-up of any ongoing adverse reactions was conducted by the study investigational site.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Northern Ireland
-
Belfast, Northern Ireland, United Kingdom, BT9 6AD
- Celerion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Subject has smoked continuously for at least the last 3 years prior to the Screening visit.
- Subject has smoked ≥ 10 commercially available cigarettes per day for 4 weeks prior to Screening Visit and Admission. Smoking status will be verified based on a urinary cotinine test (cotinine ≥ 500 ng/mL).
- Subject does not plan to quit using tobacco and/or nicotine products within the next 3 months.
- Smoking, healthy subject as judged by the Investigator or designee based on available assessments from the Screening period.
Main Exclusion Criteria:
- As per the Investigator's judgment, the subject cannot participate in the study for any reason other than medical.
- Subject is legally incompetent, or physically or mentally incapable of giving consent.
- Subject has a clinically relevant disease that requires medication, which as per the judgment of the Investigator would jeopardize the safety of the subject.
- Subject has donated or received whole blood or blood products within 30 days prior to Screening Visit.
- Subject has a BMI < 18.5 kg/m2 or > 32.0 kg/m2 (Europe) or > 35.0 kg/m2 (USA).
- For women only: subject is pregnant (does not have negative pregnancy test at Screening Visit and at Admission) or is breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: NP-1
Nicotine Pouch 1.0 (variant NP-1)
|
NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Velo-NP; 10 mg nicotine;
Zyn-NP; 3 mg nicotine;
|
|
Experimental: NP-2
Nicotine Pouch 1.0 (variant NP-2)
|
NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Velo-NP; 10 mg nicotine;
Zyn-NP; 3 mg nicotine;
|
|
Experimental: NP-3
Nicotine Pouch 1.0 (variant NP-3)
|
NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Velo-NP; 10 mg nicotine;
Zyn-NP; 3 mg nicotine;
|
|
Experimental: NP-4
Nicotine Pouch 1.0 (variant NP-4)
|
NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Velo-NP; 10 mg nicotine;
Zyn-NP; 3 mg nicotine;
|
|
Active Comparator: Velo-NP
Velo® Ice Cool
|
NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Velo-NP; 10 mg nicotine;
Zyn-NP; 3 mg nicotine;
|
|
Active Comparator: Zyn-NP
Zyn® Cool Mint Mini Dry
|
NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Velo-NP; 10 mg nicotine;
Zyn-NP; 3 mg nicotine;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Background-corrected Maximum Plasma Concentration [Cmax]
Time Frame: T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
|
To measure the background-corrected maximum plasma concentration [Cmax] of 4 variants of NP 1.0 nicotine pouches compared to Velo-NP and Zyn-NP in healthy smokers from a 30 minutes product use period.
|
T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
|
|
Background-corrected Time to the Maximum Concentration [Tmax]
Time Frame: T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
|
To measure the background-corrected time to the maximum concentration [Tmax] of 4 variants of NP 1.0 nicotine pouches compared to Velo-NP and Zyn-NP in healthy smokers from a 30 minutes product use period.
|
T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
|
|
Area Under the Background-corrected Concentration-time Curve (AUC) From Start of Product Use, Extrapolated to Infinity (AUC Infinity)
Time Frame: T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
|
To measure the area under the background-corrected concentration-time curve (AUC) from start of product use of 4 variants of NP 1.0 nicotine pouches compared to Velo-NP and Zyn-NP in healthy smokers from a 30 minutes product use period.
|
T0 = start of product use. Blood was drawn 5 minutes prior to T0, and then 5, 10, 15, 20, 25, 30, 35, 40 minutes, 1, 3, and 6 hours after T0, on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Score of Cigarette Craving by the Visual Analog Scale (VAS)-Craving Assessment
Time Frame: Measured before, and up to 6 hours post-product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
To measure cigarette craving by the visual analog scale (VAS)-craving assessment in healthy smokers following a 30 minutes product use period of 4 variants of Nicotine pouch 1.0 compared to Velo-NP and Zyn-NP.
Craving was assessed at selected time points on a scale from "no craving" (0 mm) to "strong craving" (100 mm) by measuring the number of millimeters (0-100 mm) from the "no craving" point to the point at which the drawn line intersected the scale.
|
Measured before, and up to 6 hours post-product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
|
Score of "in the Moment" Product Liking by the VAS-liking Assessment
Time Frame: Measured up to 1 hour post-product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
To measure "in the moment" product liking by the VAS-liking assessment in healthy smokers following a 30 minutes product use period of 4 variants of Nicotine pouch 1.0 compared to Velo-NP and Zyn-NP.
Product liking was assessed at selected time points on a scale from "strong disliking" (0 mm) to "strong liking" (100 mm) by measuring the number of millimeters (0-100 mm) from the "strong disliking" point to the point at which the drawn line intersected the scale.
|
Measured up to 1 hour post-product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
|
Score of Overall Product Liking by the VAS-liking Assessment
Time Frame: Measured after 30 minutes product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
To measure overall product liking by the VAS-liking assessment in healthy smokers following a 30 minutes product use period of 4 variants of Nicotine pouch 1.0 compared to Velo-NP and Zyn-NP.
Overall product liking was assessed at selected time points on a scale from "strong disliking" (0 mm) to "strong liking" (100 mm) by measuring the number of millimeters (0-100 mm) from the "strong disliking" point to the point at which the drawn line intersected the scale.
|
Measured after 30 minutes product use on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
|
Score of Product Satisfaction by the VAS-satisfaction Assessment
Time Frame: Measured on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
To measure product satisfaction by the VAS-satisfaction assessment in healthy smokers following a 30 minutes product use period of 4 variants of Nicotine pouch 1.0 compared to Velo-NP and Zyn-NP.
Product satisfaction was was assessed at selected time points on a scale from "not at all" (0 mm) to "extremely" (100 mm) by measuring the number of millimeters (0-100 mm) from the "not at all" point to the point at which the drawn line intersected the scale.
|
Measured on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
|
Score of Product Intention to Use Again by the VAS-intention to Use Again Assessment
Time Frame: Measured on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
To measure intention to use product again by the VAS-intention to use again assessment in healthy smokers following a 30 minutes product use period of 4 variants of Nicotine pouch 1.0 compared to Velo-NP and Zyn-NP.
Intention to use again was was assessed at selected time points on a scale from "very unlikely" (0 mm) to "very likely" (100 mm) by measuring the number of millimeters (0-100 mm) from the "very unlikely" point to the point at which the drawn line intersected the scale.
|
Measured on day 1 (morning/afternoon), day 2 (morning/afternoon), and day 3 (morning/afternoon)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rajkumar Chetty, MD, Celerion
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- P5-PK-01-EXP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.